Compare SLG & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLG | PBLS |
|---|---|---|
| Founded | 1980 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.6B |
| IPO Year | 1997 | 2026 |
| Metric | SLG | PBLS |
|---|---|---|
| Price | $58.17 | $38.90 |
| Analyst Decision | Buy | |
| Analyst Count | 19 | 0 |
| Target Price | ★ $50.63 | N/A |
| AVG Volume (30 Days) | ★ 803.0K | 345.6K |
| Earning Date | 04-15-2026 | N/A |
| Dividend Yield | ★ 7.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,003,046,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.18 | N/A |
| 52 Week Low | $34.77 | $25.56 |
| 52 Week High | $66.29 | $41.49 |
| Indicator | SLG | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 60.22 | 59.45 |
| Support Level | $43.50 | $38.00 |
| Resistance Level | N/A | $41.49 |
| Average True Range (ATR) | 1.62 | 2.16 |
| MACD | -0.03 | -0.15 |
| Stochastic Oscillator | 66.22 | 55.44 |
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 31.4 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.